Investor Relations

Investor Relations

NattoPharma ASA, based in Oslo, Norway, invests heavily in research and development to identify the health benefits and market opportunities for its branded ingredients. The exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, NattoPharma has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus.